Average Cost of Developing New Pharmaceutical

The cost of developing new medications might not be as steep as we think. Recent research from RAND Corporation reveals that a few exceptionally expensive drugs have been inflating the average cost of drug development, leading to skewed public perceptions about research and development expenses.

A unique approach was used to analyze spending on research and development for 38 newly FDA-approved drugs. The study found that while the average cost of developing a new drug was $369 million, the median cost was actually much lower at $150 million.

After adjusting for potential earnings from alternative investments and failed drugs, the median cost increased to $708 million, with the average cost reaching $1.3 billion due to a small number of high-cost outliers. Excluding just two drugs brought the average cost down to $950 million, a 26% decrease.

These findings challenge the notion that drug development is prohibitively expensive and suggest that the typical cost may not be as astronomical as previously assumed. The study’s lead author, Andrew Mulcahy, emphasizes the importance of accurate cost estimates for evaluating incentives like patent regulatory exclusivity that ensure fair returns on investment for drug developers.

The research highlights the critical role of drug research and development in driving medical breakthroughs, such as COVID-19 treatments and hepatitis C cures. It also addresses the ongoing debate surrounding U.S. drug pricing regulations and their impact on investments in new drugs.

By scrutinizing public disclosures of research and development spending reported to the SEC, researchers shed light on the true costs of developing new drugs. The study’s innovative methodology offers a more comprehensive understanding of research and development expenses, emphasizing the need for nuanced policy discussions on drug costs in the U.S.

This study, supported by Arnold Ventures, underscores the importance of accurate cost assessments for informing discussions on drug development and pricing. The researchers suggest that using the median cost, rather than the average, provides a more realistic perspective on the expenses involved in bringing new drugs to market.